2nd Annual Outsourcing in Clinical Trials Southeast7-8 May 2013, Embassy Suites Raleigh-Durham/Research Triangle, Cary, NC
Outsourcing in Clinical Trials Southeast was Arena International’s best launch event of 2012 and it is set to become one of the most successful conferences in the Outsourcing series. Catering to the industry based in North Carolina and surrounding states, this conference offers a fantastic local event for the Southeast hub.
With a focus on offering new and worthwhile content, we will soon be welcoming an OCT Southeast Advisory Board, made up from experts in the local industry who will play a key role in ensuring the agenda content is exactly what clinical outsourcing professionals need to know so that attendees can be sure their experience will be truly valuable.
The 2nd Annual Outsourcing in Clinical Trials Conference Southeast is a fantastic platform for biotech, pharma and medical device professionals from the RTP area to discuss the specific challenges they face on day-to-day basis. The beauty of this unique event is its local reach and its specifically tailored topics which will help you to achieve better results from your outsourcing programs.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news.
Primary delegates for this event are those with responsibility for outsourcing in biotech, pharma and medical device companies around the Research Triangle. Including;CEO/CMO/CSO/CFOGlobal Head, Head, VP, Director:Clinical OperationsClinical ResearchOutsourcing / sourcing / procurement / alliancesGlobal Head, Head, VP, Director:Clinical TrialsProject Management
Testimonials from the 2012 Outsourcing in Clinical Trials Southeast Conference……..
You really chose a great group of presenters who were knowledgeable, well-spoken and approachable. The talks kept building on the theme which assured a great learning experience. The round table idea was a great success in this setting. Bravo
Last week, our team was fortunate enough to be able to join 28 other exhibitors at the second annual Outsourcing in Clinical Trials Southeast conference. Held at the Embassy Suites in Research Triangle Park, N.C., the event attracted a diverse blend of biotech, pharma and medical device companies.
Takeda Pharmaceutical Company has began its TOURMALINE-MM2 phase 3 trial of MLN9708 in patients with newly diagnosed multiple myeloma.
Clinical-stage biopharmaceutical company Protalex has reported positive interim review of phase 1b trial of PRTX-100 in rheumatoid arthritis (RA) by an independent data safety monitoring committee.
Speciality pharmaceutical company Prosonix has began the PSX1002 Phase 2 study in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Jennerex Biotherapeutics has announced completion of enrolment in Phase 2b trial of Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of liver cancer.
Dupilumab targets the alpha subunit of the interleukin 4 receptor (IL-4R alpha), which modulates signaling of both IL-4 and IL-13, drivers of Th2 (Type 2 helper T cell) immune response.
Research-based biopharmaceutical company AbbVie has started Phase 3 in study of investigational compound atrasentan on renal outcomes in patients with diabetic nephropathy.
R-Tech Ueno has started patient enrolment in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in the US for treating severe dry eye.
Pfizer has stopped the Phase 3 randomised, open-label study (B1931008) of inotuzumab ozogamicin in relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL).